Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Phase 2 Completed 37 enrolled Abramson Cancer Center at Penn Medicine

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to see how well the combination of Abraxane and gemcitabine works in people with advanced adenocarcinoma NSCLC who have already had treatment for their disease. Gemcitabine and Abraxane are FDA approved chemotherapies; however, the FDA has not approved this combination in the treatment of this specific type of cancer. Patients may continue to receive the study drugs until their disease gets worse or they have unacceptable side effects.

Timeline

Start: 2015-06-26
Primary completion: 2020-04-30
Completion: 2020-04-30

Publications

Ciunci CA, Reibel JB, Evans TL, Mick R, Bauml JM, Aggarwal C, Marmarelis ME, Singh AP, D'Avella C, Cohen RB, Langer CJ. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed. Clin Lung Cancer. 2022 Jun;23(4):e310-e316. doi: 10.1016/j.cllc.2022.02.004. Epub 2022 Mar 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abraxane	Small molecule	100 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous

Indications

No indication recorded.